<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Raz, Itamar</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Characterizing Hypoglycemic Events during Saxagliptin Treatment in Type 2 Diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-19</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment of type 2 diabetes mellitus (T2DM) with saxagliptin increased the risk of major and minor hypoglycemic events, but it enabled more patients to reach an HbA1C target of less than 7% without hypoglycemia. This is according to a subanalysis of the Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications? study [SAVOR-TIMI 53; NCT01107886]. The main results of this multicenter, randomized, double-blind, placebo-controlled Phase 4 study have been published [Scirica BM et al. N Engl J Med 2013].</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>